All articles by Catherine Eckford (European Pharmaceutical Review) – Page 4
-
NewsLilly acquires CAR-T therapy biotech Orna Therapeutics for $2.4bn
Agreement with Orna Therapeutics includes potential best-in-class, immune-targeting in vivo CAR-T therapies.
-
NewsBMS partners with Evinova to strengthen clinical development using AI
Aims to shorten medicine development timelines, improve likelihood of trial success and reduce clinical trial costs.
-
NewsRoche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis
New phase III data presented at ACRIMS suggests the oral BTK inhibitor could become a first-in-class multiple sclerosis therapy.
-
NewsTitanium dioxide-free drotaverine hydrochloride tablets developed
Study findings indicate an alternative coating that would comply with potential future regulation against use of titanium dioxide as a pharmaceutical excipient.
-
NewsGSK’s Nucala green lit for COPD in expanded EU approval
The EC's decision opens up the monthly biologic for use by COPD patients with an eosinophils phenotype.
-
NewsCrystallisation research could enhance API drug production
Thermodynamic framework supports rapid assessment of solvents during active pharmaceutical ingredient (API) manufacturing.
-
NewsAstraZeneca’s Imfinzi plus chemotherapy earns CHMP nod in gastric cancer
If approved, the regimen would become the first immunotherapy-based perioperative therapy for adults with early gastric and gastroesophageal cancers in Europe.
-
NewsNMD Pharma will ‘accelerate’ rare disease drug ignaseclant despite endpoint miss
But phase II data of the small molecule inhibitor for Charcot-Marie-Tooth disease Types 1 and 2 did show it meeting secondary endpoints for functional improvements.
-
NewsGenentech gains rights to SanegeneBio’s RNAi pipeline for $1.5bn
Licensing agreement with SanegeneBio set to advance potential breakthrough siRNA medicines.
-
NewsUCB wins CHMP favour for first thymidine kinase 2 deficiency treatment
If approved by the European Commission, Kygevvi would provide a new treatment option for eligible patients with the ultra-rare mitochondrial disease in Europe.
-
NewsFDA launches PreCheck pilot programme for US pharma manufacturers
The regulator’s new programme aims to create more efficient regulatory review processes for new pharmaceutical manufacturing facilities.
-
NewsDr David Berman to join Moderna as Chief Development Officer
Meanwhile, Dr Jacqueline Miller is stepping down as the company's Chief Medical Officer.
-
NewsLilly chooses Pennsylvania for $3.5bn injectables manufacturing facility
Investment in the Lehigh Valley site finalises the last of the pharma company’s four new US manufacturing plants, supporting its onshoring of domestic medicine production.
-
NewsAstraZeneca makes $15bn manufacturing investment in China
Landmark, decade-long investment plan aims to support the pharma company’s 2030 revenue objective of $80 billion.
-
NewsModerna and Recordati collaborate on rare disease mRNA therapy
License agreement set to advance mRNA-3927, a potential disease modifying therapy for the rare metabolic disorder propionic acidemia.
-
NewsRoche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
-
NewsPharma benefits in EU-India Free Trade Agreement
Conclusion of ‘landmark’ deal significantly enhances trade, investment and supply chains, notably granting beneficial tariff reductions for the pharma industry.
-
NewsFMT shows promise for enhancing immunotherapy effectiveness in advanced cancer
Phase II data derived from the first randomised trial comparing immunotherapy outcomes post-FMT from immunotherapy responders versus placebo.
-
NewsInnovative nanoparticle research could restore antibiotic efficacy
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
-
NewsIpsen selects Pierrick Lefranc as new EVP Technical Operations
He brings 30 years of pharma industry experience to the role, principally in key manufacturing projects.